Clinical Trials Directory

Trials / Completed

CompletedNCT03125629

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

Comparison of PET/CT vs. PET/MRI

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
53 (actual)
Sponsor
Stanford University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate if PET/CT and PET/MRI scanners provide equivalent results for evaluation of cancer patients. OUTLINE: Patients receive standard of care 18F-fludeoxyglucose (FDG) or Ga68-DOTA-TATE intravenously (IV). Within 45-60 minutes, patients then undergo PET/CT imaging immediately followed by PET/MRI. Each participant is to receive 18-FDG or 68Ga-DOTA-TATE only, no participant was to receive both radiotracers.

Conditions

Interventions

TypeNameDescription
DRUGF-18 FDGRadiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
DRUGGa-68-DOTA-TATERadiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
DEVICEPositron Emission Tomography / Computed Tomography (PET/CT) ScanScan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
DEVICEPositron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) ScanScan using a NOVEL GE PET/MRI scanner.

Timeline

Start date
2014-05-27
Primary completion
2016-11-30
Completion
2020-02-05
First posted
2017-04-24
Last updated
2021-04-09
Results posted
2021-04-08

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03125629. Inclusion in this directory is not an endorsement.